F. Cosci, F. Rotella, G. Barbieri, L. Natrella, S. Gorini Amedei, R. Bitorzoli, C. Faravelli - Vol. 10, December 2004, Issue 4
Testo Immagini Bibliografia Summary Indice
Gli induttori del panico: una rassegna
ragionata
Panic inducers: a critical review
1 American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (ed. 4). Washington DC 1994.
2 Tyrer P, ed. Psychopharmacology and anxiety. London, Oxford: Oxford University Press 1990.
3 Pitts FN, McClure JN Jr. Lactate metabolism in anxiety neurosis. N Engl J Med 1992;277:1329-36.
4 Gorman JM, Askanazi J, Liebowitz MR, Fyer AJ, Stein J, Kinney JM, et al. Response to hyperventilation in a group of patients with panic disorder. Am J Psychiatry 1984;141:857-61.
5 Griez EJ, Lousberg H, van den Hout MA, van der Molen GM. CO2 vulnerability in panic disorder. Psychiatry Res 1987;20:87-95.
6 Van den Hout MA, Griez E. Panic symptoms after inhalation of carbon dioxide. Br J Psychiatry 1984;144:503-7.
7 Griez E, Pols HJ, van den Hout MA. Acid-base balance in real life panic. J Affect Disord 1987;12:263-6.
8 Soldates C, Rabavilles A. Psychiatry today. Amsterdam, the Netherlands: Elsevier Sciences Publisher 1990.
9 Sanderson WC, Wetzler S. Five percent carbon dioxide challenge: valid analogue and marker of panic disorder? Biol Psychiatry 1990;27:689-701.
10 De Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch Gen Psychiatry 1989;46:511-7.
11 Bradwejn J, Koszycki D, Payeur R, Bourin M, Borthwick H. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Am J Psychiatry 1992;149:962-4.
12 Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 1991;48:603-10.
13 Bradwejn J, Koszycki D. Imipramine antagonises the panicogenic effect of CCK4 in panic disorder patients. Am J Psychiatry 1994;151:261-3.
14 Beinfeld MC, Meyer DK, Eskay RL, Jensen RT, Brownstein MJ. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res 1981;212:51-7.
15 Branchereau P, Bohme GA, Champagnat J, Morin-Surun MP, Durieux C, Blanchard JC, et al. Cholecystokinin-A and Cholecystokinin-B receptors in neurons of the brainstem solitary complex of the rat: pharmacological identification. J Pharmacol Exp Ther 1992;260:1433-40.
16 Bradwejn J, Koszycki D, Couteoux Du Teatre A, Bourin M, Palmour R, Ervin F. The cholecystokinin hypothesis of panic anxiety disorders: a review. J Psychopharmacol 1992;6:345-51.
17 Flint AJ. Epidemiology and comorbidity of anxiety disorders in the elderly. Am J Psychiatry 1994;151:640-9.
18 Tang F, Man WS. The regional distribution of thyrotropin releasing hormone, leu-enkephalin, met-enkephalin, substance P, somatostatin and cholecystokinin in threat brain and pituitary. Neuropeptides 1991;19:287-92.
19 Clark DM. A cognitive approach to panic. Behav Res Ther 1986;24:461-70.
20 Nutt D, Lawson C. Panic attacks: a neurochemical overview of models and mechanisms. Br J Psychiatry 1992;47:917-25.
21 Maurer K. Imaging of the Brain in Psychiatry and Related Fields. Berlin: Springer Verlag 1992.
22 Rainey JM Jr, Frohman CE, Freedman RR, Pohl RB, Ettedgui E, Williams R. Specificity of lactate infusion as a model of anxiety. Psychopharmacol Bull 1984;20:45-9.
23 Cowley DS, Dager SR, Dunner DL. Lactate infusions in major depression without panic attacks. J Psychiatr Res 1987;21:243-8.
24 Faravelli C, Servi P, Paterniti S, Scarpato MA, Spiti R, Biondi F. The origin of panic/agoraphobia: an integrated view. Ital J Psychiatr Behav Sci 1993;3:157-66.
25 Otte C, Kellner M, Arlt J, Jahn H, Holsboer F, Wiedemann K. Prolactin but not ACTH increases during sodium lactate-induced panic attacks. Psychiatry Res 2002;109:201-5.
26 Dager SR, Marro KI, Richards TL, Metzger GD. Preliminary application of magnetic resonance spectroscopy to investigate lactate-induced panic. Am J Psychiatry 1994;151:57-63.
27 Den Boer JA, Westenberg HG, Klompmakers AA, Van Lint LE. Behavioral biochemical and neuroendocrine concomitants of lactate-induced panic anxiety. Biol Psychiatry 1989;26:612-22.
28 Aronson TA, Carasiti I, McBane D, Whitaker-Azmitia P. Biological correlates of lactate sensitivity in panic disorder. Biol Psychiatry 1989;26:463-77.
29 Coplan JD, Goetz R, Klein DF, Papp LA, Fyer AJ, Liebowitz MR, et al. Plasma cortisol concentrations preceding lactate-induced panic. Psychological, biochemical, and physiological correlates. Arch Gen Psychiatry 1998;55:130-6.
30 George DT, Lindquist T, Nutt DJ, Ragan PW, Alim T, McFarlane V, et al. Effect of chloride or glucose on the incidence of lactate-induced panic attacks. Am J Psychiatry 1995;152:692-7.
31 Hollander E, Liebowitz MR, Gorman JM, Cohen B, Fyer A, Klein DF. Cortisol and sodium lactate induced panic. Arch Gen Psychiatry 1989;46:135-40.
32 Gaffney FA, Fenton BJ, Lane LD, Lake CR. Hemodynamic, ventilatory, and biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks. Arch Gen Psychiatry 1988;45:53-60.
33 Liebowitz MR, Gorman JM, Fyer AJ, Levitt M, Dillon D, Levy G, et al. Lactate provocation of panic attacks. II. Biochemical and physiological findings. Arch Gen Psychiatry 1985;42:709-19.
34 Fyer AJ, Gorman JM, Liebowitz MR, Levitt M, Danielson E, Martinez J, et al. Sodium lactate infusion, panic attacks, and ionized calcium. Biol Psychiatry 1984;19:1437-47.
35 Woods SW, Charney DS, Goodman WK, Heninger GR. Carbon dioxide-induced anxiety. Behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects. Arch Gen Psychiatry 1988;45:43-52.
36 Martinez JM, Coplan JD, Browne ST, Goetz R, Welkowitz LA, Papp LA, et al. Hemodynamic response to respiratory challenges in panic disorder. J Psychosom Res 1998;44:153-61.
37 Sasaki I, Akiyoshi J, Sakurai R, Tsutsumi T, Ono H, Yamada K, et al. Carbon dioxide induced panic attack in panic disorder in Japan. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:1145-57.
38 Antony MM, Brown TA, Barlow DH. Response to hyperventilation and 5,5% CO2 inhalation of subjects with types of specific phobia, panic disorder, or no mental disorder. Am J Psychiatry 1997;154:1089-95.
39 Bystritsky A, Shapiro D. Continuous physiological changes and subjective reports in panic patients: a preliminary methodological report. Biol Psychiatry 1992;32:766-77.
40 Valença AM, Nardi AE, Nascimento I, Zin WA, Versani M Respiratory panic disorder subtype and sensitivity to the carbon dioxide challenge test. Braz J Med Biol Res 2002;35:783-8.
41 Fyer MR, Uy J, Martinez J, Goetz R, Klein DF, Fyer A, et al. CO2 challenge of patients with panic disorder. Am J Psychiatry 1987;144:1080-2.
42 Papp LA, Martinez JM, Klein DF, Coplan JD, Norman RG, Cole R, et al. Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. Am J Psychiatry 1997;154:1557-65.
43 Bradwejn J, LeGrand JM, Koszycki D, Bates JH, Bourin M. Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. Am J Psychiatry 1998;155:280-2.
44 Wiedemann K, Jahn H, Yassouridis A, Kellner M. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch Gen Psychiatry 2001;58:371-7.
45 Knott V, Mahoney C, Bradweijn, Shlik J, Giunnarson T. Effects of acute cholecystokinin infusion on hemispheric EEG asymmetry and coherence in healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:179-84.
46 Zwanzger P, Eser D, Aicher S, Schule C, Baghai TC, Padberg F, et al. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology 2003;28:979-84.
47 Strohle A, Kellner M, Holsboer F, Wiedemann K. Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. Am J Psychiatry 2001;158:1514-6.
48 Strohle A, Holsboer F, Rupprecht R. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacology 2000;22:251-6.
49 Jerabek I, Boulenger JP, Bradwejn J, Lavallee YJ, Jollicoeur FB. CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects. Eur Neuropsychopharmacol 1999;9:149-55.
50 Van Megen HJ, Westenberg HG, Den Boer JA, Kahn RS. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder. Eur Neuropsychopharmacol 1996;6:187-94.
51 Koszycki D, Bradwejn J, Bourin M. Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers. Eur Neuropsychopharmacol 1991;1:137-41.